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complete response (no vomiting and no rescue antiemetic use
0-120 hours after chemotherapy).
If we are to optimize the care of our patients, we need to stan-
dardize CINV study end points. We would also request that all of the
currently published studies allow open access to their full data so that
this process can begin.5 This would allow clinicians and patients to
compare different regimens on a more level playing field. Standard-
ization of data collection and reporting would also allow objective
cross-trial comparisons and meta-analyses to better inform treatment
guidelines and health policy. Finally, if we as oncologists are unable to
decide which end points to report, then surely it is time to ask our
patients what they believe to be the most important clinical parame-
ters that should be measured and reported in the real-world setting?
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Aprepitant Versus Dexamethasone for
Delayed Emesis: What Is the Role of
the 5-Hydroxytryptamine Type 3
Receptor Antagonist Palonosetron?
TO THE EDITOR: We would like to comment on the recently
published study by Roila et al1 and to respond to the authors’ discus-
sion of our own work. The hypothesis underlying the study was that in
the pivotal trial by Warr et al,2 aprepitant had proved superior to
ondansetron against delayed emesis as the result of a carryover effect
on the protection against acute emesis caused by an anthracycline plus
cyclophosphamide (AC). The current superiority trial,1 which was
prematurely closed because of accrual difficulties, suggests that either
aprepitant or dexamethasone can be recommended, but because of
the lower cost of corticosteroids, dexamethasone should be chosen as
prophylaxis for delayed emesis caused by AC.
The authors highlight that only an appropriate methodology
allows us to identify the role of an agent in the delayed phase. In view
of this, we do not understand the decision of the investigators to
use palonosetron; we also fail to understand why there is no com-
ment about it in the article.1 The choice of palonosetron as the
5-hydroxytriptamine type 3 receptor antagonist can represent a meth-
odologic pitfall for a trial that is designed to target delayed emesis. A
large superiority trial comparing palonosetron with granisetron,
both combined with dexamethasone given once per day for 3
days, demonstrated that the complete response (CR) was simi-
lar in the acute phase but significantly superior with palonose-
tron in the delayed phase (57% v 44.5%; P .001) in the setting of
cisplatin and AC chemotherapy.3 In a noninferiority trial comparing
palonosetron plus either dexamethasone given once or once per day
for 3 days, the dexamethasone-sparing regimen achieved delayed pro-
tection similar to that found with multiday dexamethasone dosing4
(Table 1). The 1-day regimen that included low-dose dexamethasone
provided protection against acute emesis similar to that observed in
the control arm (ondansetron plus high-dose dexamethasone) of the
trial by Warr et al,2 but a higher proportion of women receiving the
dexamethasone-sparing regimen experienced delayed CR compared
with those receiving ondansetron also on days 2 and 3 (Table 1). And
last but not least, the recent results of a large phase III trial by Aapro et
al5 indicate that palonosetron plus a single, day-1-only, 20-mg dose of
dexamethasone provided acute protection similar to that of the three-
drug regimen used in the trial by Roila et al1 and also achieved delayed
CR in the vast majority of patients (Table 1). These results are partic-
ularly relevant to clinical practice if clinicians choose not to use a
neurokinin-1 receptor antagonist (NK-1RA). Acute and delayed find-
ings from this trial5 also compare well with those observed in the
pivotal trial by Warr et al2 (Table 1). Likewise, the delayed CR rate that
was observed in the second Aapro trial5 confirms and reinforces pre-
vious results showing that not all women undergoing AC need addi-
tional dexamethasone doses when a combination of palonosetron
plus dexamethasone is administered on day 1.4,6
We regret that despite this evidence, the article by Roila et al1 is
remarkable for the absence of any attempt to place the findings in the
contextofotherexistingandrelevantknowledge.Theauthorsshouldalso
have a more conservative approach when they speculate on the meaning
of their findings. In daily clinical practice, an Italian patient would
need to take a large number of dexamethasone tablets (available
only at a dose of either 0.5 or 0.75 mg) to comply with the
recommended daily dose of 8 mg for delayed prophylaxis.
Therefore, the choice between the two drugs should be made
after considering not only the differences in terms of efficacy,
safety, and cost, but also feasibility and convenience. Our opin-
ion is not that dexamethasone would be ineffective against
delayed emesis, as erroneously stated by the authors. However,
we can customize the prophylaxis to avoid giving unnecessary
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additional doses (and adverse effects such as insomnia and
heartburn) of dexamethasone to women undergoing AC. It
would seem important to note that recent results of treatment
with a fixed-dose combination of the NK-1RA netupitant and
palonosetron plus 1-day dexamethasone further demonstrate
the value of a simplified, single-day prophylaxis5 (Table 1).
The use of palonosetron does not allow us to be confident that the
same CR results in the delayed phase would be obtained if an older
antagonist was administered on day 1. It seems unreasonable to use
only one of the three capsules available in the aprepitant package. In
daily clinical practice, real options for antiemetic prophylaxis in pa-
tients undergoing AC still remain: either the 3-day standard aprepitant
regimen (fosaprepitant is not available in Italy) or palonosetron plus
dexamethasone, as recommended by guidelines, when an NK-1RA is
not available.7,8
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Table 1. Phase III Trials With Different Antiemetic Regimens in Patients With Breast Cancer Undergoing AC Treatment
Author and Year Antiemetic Treatment
No. of
Patients
Study
Period
CR (%)
PExp Control
Warr et al, 20052 Exp: Day 1: APR  ONDA  DEX (12 mg) 433 Day 1 76 69 .03
Days 2 and 3: APR
Control: Day 1: ONDA  DEX (20 mg) 424 Days 2-5 55 49 .06
Days 2 and 3: ONDA
Aapro et al, 20104 Exp: Day 1: PALO (0.25 mg)  DEX (8 mg) 151 Day 1 69.5 68.5 .57
Days 2 and 3: placebo
Control: Day 1: PALO (0.25 mg)  DEX (8 mg) 149 Days 2-5 62 66 .25
Days 2 and 3: DEX (8 mg)
Roila et al, 20141 Exp: Day 1: APR  PALO (0.25 mg)  DEX (8 mg) 273 Day 1 88 85 .39
Days 2 and 3: DEX (8 mg)
Control: Day 1: APR  PALO (0.25 mg)  DEX (8 mg) 278 Days 2-5 79.5 79.5 1.00
Days 2 and 3: APR
Aapro et al, 20132 Exp: Day 1: NEPA  DEX (12 mg) 724 Day 1 88 85 .04
Control: Day 1: PALO (0.50 mg)  DEX (20 mg) 725 Days 2-5 77 69.5 .001
Abbreviations: AC, anthracycline plus cyclophosphamide; APR, standard-dose aprepitant; CR, complete response (no vomiting and no rescue antiemetics); DEX,
dexamethasone; Exp, experimental; NEPA, combination of netupitant and palonosetron; ONDA, ondansetron (8 mg twice per day orally); PALO, palonosetron (0.25
mg intravenously or 0.50 mg orally).
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